Cell Source Inc. Financials
CLCS
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | – | – | – | – | – |
| General & Administrative | $2 | $2 | $3 | $2 | $3 | $3 |
| Research & Development | $1 | – | – | $2 | $1 | $1 |
| Total Operating Expenses | $4 | $4 | $4 | $4 | $4 | $4 |
| Operating Income | – | -$4 | -$4 | -$4 | -$4 | -$4 |
| Non-Operating | ||||||
| Net Interest Expense | – | – | – | – | -$1 | -$0 |
| Other Non-Operating Income (Expense) | $0 | -$1 | -$1 | -$1 | -$1 | -$0 |
| EBT (Earnings Before Tax) | – | -$5 | -$5 | -$5 | -$5 | -$5 |
| Income Tax Expense | – | – | $0 | $0 | $0 | $0 |
| Net Income | ||||||
| Net Income | -$4 | -$5 | -$5 | -$5 | -$5 | -$5 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | – | – | – | – | – |
| EPS (Basic) | -$0.04 | -$0.14 | -$0.17 | -$0.18 | -$0.19 | -$0.16 |
| EPS (Diluted) | -$0.04 | -$0.14 | -$0.17 | -$0.18 | -$0.19 | -$0.16 |
| Weighted Avg Shares (Basic) | 25.6M | 41.9M | 37.8M | 34.8M | 33.1M | 29.1M |
| Weighted Avg Shares (Diluted) | 25.6M | 41.9M | 37.8M | 34.8M | 33.1M | 29.1M |
| Shares Outstanding | 25.6M | 41.9M | 37.8M | 34.8M | 33.1M | 29.1M |
Cell Source (CLCS) financials: revenue, profit and margins
Cell Source (CLCS) generated about n/a in revenue and -$5 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Cell Source profitable?+
Cell Source reported about -$5 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 13 May 2026, covering the period ending 31 Mar 2025, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with CLCS
Spot a number that looks wrong? Check it in CLCS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CLCS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.